Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer | Clinical Cancer Research https://t.co/I0ttWMPUup
RT @NM_Urology: Adam Weiner, MD, and colleagues sought to characterize AR-activity in localized prostate cancer and understand its molecula…
Great collaborative work from a multi-institutional team.
Adam Weiner, MD, and colleagues sought to characterize AR-activity in localized prostate cancer and understand its molecular and clinical implications. Due to the implications of AR-activity in treating naïve primary prostate cancer is largely unknown. htt
RT @CCR_AACR: Read the article here: https://t.co/YMK1KDzdmR https://t.co/PQ3PzF8Eb9
Read the article here: https://t.co/YMK1KDzdmR
Adam Weiner, MD, and colleagues sought to characterize AR-activity in localized prostate cancer and understand its molecular and clinical implications. Due to the implications of AR-activity in treatment naïve primary prostate cancer is largely unknown. ht
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer https://t.co/4jthuWE8We
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer | Clinical Cancer Research @DrSpratticus 👍🏼 https://t.co/GqjKedh3qX
Double Wow
19,470 patients! WOW Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer https://t.co/BWFl9NYF1i
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer https://t.co/uhrbWE8ShF
RT @NM_Urology: Adam Weiner, MD, and colleagues sought to characterize AR-activity in localized prostate cancer and understand its molecula…
RT @NM_Urology: Adam Weiner, MD, and colleagues sought to characterize AR-activity in localized prostate cancer and understand its molecula…
Adam Weiner, MD, and colleagues sought to characterize AR-activity in localized prostate cancer and understand its molecular and clinical implications. Due to the implications of AR-activity in treatment naïve primary prostate cancer being largely unknown.
RT @rdittamore: Important work in understanding AR heterogeneity & low AR signaling in large patient cohorts in early prostate cancer. Pos…
RT @NM_Urology: New large collaborative effort! @EdwardSchaeffer et al. identify an aggressive subtype of localized #prostatecancer with lo…
We also found in our small cohort a subgroup with low AR activity https://t.co/Pf5OQXqSsZ Here a great study reporting the clinical implications! Large cohorts #ProstateCancer #androgenreceptor
RT @NM_Urology: New large collaborative effort! @EdwardSchaeffer et al. identify an aggressive subtype of localized #prostatecancer with lo…
New large collaborative effort! @EdwardSchaeffer et al. identify an aggressive subtype of localized #prostatecancer with low androgen receptor activity @DrSpratticus @Davicioni @Adam_Weiner535 @ArulChinnaiyan @CCR_AACR @PCF_Science @PCFnews @LurieCancer ht
RT @rdittamore: Important work in understanding AR heterogeneity & low AR signaling in large patient cohorts in early prostate cancer. Pos…
RT @rdittamore: Important work in understanding AR heterogeneity & low AR signaling in large patient cohorts in early prostate cancer. Pos…
RT @rdittamore: Important work in understanding AR heterogeneity & low AR signaling in large patient cohorts in early prostate cancer. Pos…
RT @rdittamore: Important work in understanding AR heterogeneity & low AR signaling in large patient cohorts in early prostate cancer. Pos…
RT @rdittamore: Important work in understanding AR heterogeneity & low AR signaling in large patient cohorts in early prostate cancer. Pos…
Important work in understanding AR heterogeneity & low AR signaling in large patient cohorts in early prostate cancer. Possible implications of non-prediction of AR inhibitors and positive prediction of PARPi & platinum @DrSpratticus @decipher_bio
Transcriptomic heterogeneity of androgen receptor (AR) activity defines a de novo low AR-active subclass in treatment naïve primary prostate cancer https://t.co/Jv3d1Qqf4k